- Home
- LSF vs ABVC Comparison
LSF vs ABVC Comparison
Compare LSF & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- ABVC
- Stock Information
- Founded
- LSF 2015
- ABVC 2015
- Country
- LSF United States
- ABVC United States
- Employees
- LSF N/A
- ABVC N/A
- Industry
- LSF Packaged Foods
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- ABVC Health Care
- Exchange
- LSF Nasdaq
- ABVC Nasdaq
- Market Cap
- LSF 61.6M
- ABVC 52.1M
- IPO Year
- LSF 2020
- ABVC N/A
- Fundamental
- Price
- LSF $5.75
- ABVC $2.85
- Analyst Decision
- LSF Strong Buy
- ABVC
- Analyst Count
- LSF 2
- ABVC 0
- Target Price
- LSF $12.00
- ABVC N/A
- AVG Volume (30 Days)
- LSF 34.6K
- ABVC 106.1K
- Earning Date
- LSF 11-05-2025
- ABVC 11-13-2025
- Dividend Yield
- LSF N/A
- ABVC N/A
- EPS Growth
- LSF N/A
- ABVC N/A
- EPS
- LSF N/A
- ABVC N/A
- Revenue
- LSF $47,027,546.00
- ABVC $391,242.00
- Revenue This Year
- LSF $21.88
- ABVC $735.18
- Revenue Next Year
- LSF $20.86
- ABVC N/A
- P/E Ratio
- LSF N/A
- ABVC N/A
- Revenue Growth
- LSF 22.79
- ABVC 186.84
- 52 Week Low
- LSF $3.60
- ABVC $0.40
- 52 Week High
- LSF $10.90
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- LSF 43.26
- ABVC 49.62
- Support Level
- LSF $5.68
- ABVC $2.64
- Resistance Level
- LSF $5.99
- ABVC $3.14
- Average True Range (ATR)
- LSF 0.25
- ABVC 0.17
- MACD
- LSF 0.04
- ABVC -0.01
- Stochastic Oscillator
- LSF 25.21
- ABVC 42.50
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.